Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.
BioPharm America, where innovators partner to fuel the future of drug development.
The BioForward conference is designed to help life science companies connect with the best service providers. Each R&D company receives first ticket free. 10% off other tickets using our code…
Each $1 of non-dilutive funding from NIH translates into $8.38 of private sector investment in R&D. Companies which win non-dilutive funding from organizations such as BARDA, NIH, NSF, and CDMRP, are more likely to receive major equity investments.
BioFuture is a two-day, forward looking business development and investor conference designed to drive an engaging dialogue about the transformational changes taking place in the healthcare ecosystem. The conference will include plenary sessions, workshops, company presentations, investor meetings, one-on-one partnering meetings, and exhibits.
The HEALTHTECH INVESTMENT FORUM will focus on DIGITAL HEALTH, MEDTECH & DEVICES. The BIOTECH IN EUROPE FORUM is devoted to GLOBAL PARTNERING & INVESTMENT.
Advanced Therapies Europe will educate and inspire cell and gene therapy professionals in Europe, and those who wish to enter into the European market.
RESI connects start-ups, early-stage investors, and strategic channel partners maximizing fit for each technology and each company’s stage of development.
As a leading European partnering event, with 700+ participants from 30+ countries, MedFIT helps industry players find early-stage assets…
senior executive conference advancing healthcare by connecting leaders in science and industry with investors and strategic partners